Inflammatory Bowel Disease Market Size
The Global Inflammatory Bowel Disease Market reached USD 19 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 26.7 billion by 2031. The global inflammatory bowel disease market is expected to exhibit a CAGR of 4.4% during the forecast period 2024-2031.
Treatment approaches of inflammatory bowel disease include medications (such as anti-inflammatory drugs, immunosuppressants, or biological agents), lifestyle modifications, dietary changes, and, in some cases, surgery to remove or repair affected portions of the digestive tract.
Furthermore, the increasing prevalence of IBD, advancements in treatment options, and growing awareness and diagnosis of the disease are expected to drive the market growth of inflammatory bowel disease over the forecast period.
Market Summary
| Metrics | Details |
| CAGR | 4.4% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Route of Administration, Drug Class, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights. |
For more Insights Request free Sample
Market Dynamics
The Increasing Clinical Trials of Drugs for Treating Inflammatory Bowel Disease are Driving the Global Inflammatory Bowel Disease Market Growth
In May 2023, Everest Medicines, a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative medicines and vaccines, announced the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis (UC). The company will work closely with the regulatory authorities in Everest’s licensing territories and aim to file New Drug Application.
Similarly, in December 2022, Biocon Limited, an innovation-led global biopharmaceutical company, announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC. Hence, owing to the above factors, the market is expected to drive over the forecast period.
Side Effects and Safety Concerns of Inflammatory Bowel Disease Drugs are Hampering the Growth of Global Inflammatory Bowel Disease Market
Biologic medications are commonly prescribed to manage moderate-to-severe inflammatory bowel disease (IBD), but they carry the potential for significant side effects. These side effects can include infections, an increased risk of lymphoma, and joint pain. Patients with IBD are more concerned about the risk of these side effects rather than the high costs associated with these medications.
Additionally, certain medications used for IBD treatment are known to have a risk of infections, while others carry a small possibility of developing certain types of cancers. As an example, Lialda (Mesalamine) can lead to various side effects such as abdominal pain, cramps, diarrhea, gas, nausea, hair loss, headache, and dizziness.
Market Segment Analysis
The Global Inflammatory Bowel Disease Market is segmented based on type, route of administration, drug class, distribution channel, and region.
The Ulcerative Colitis Segment is Holding around 36.4% Market Share in the Market in 2022
The ulcerative colitis segment accounted for the highest market stake accounting for approximately 38.4% of the inflammatory bowel disease market in 2022. Ulcerative colitis primarily affects the colon and rectum, resulting in inflammation and ulcers in the inner lining of the large intestine. It is characterized by symptoms such as bloody diarrhea, abdominal pain, and urgency to have bowel movements.
The medication's goal of treatment is to control inflammation, relieve symptoms, and promote healing of the affected areas. The specific drugs used to treat ulcerative colitis may vary depending on the severity of the condition and individual patient factors. The commonly used medications include aminosalicylates (5-ASAs) (mesalamine, sulfasalazine, and olsalazine), as these drugs are often the first-line treatment for mild to moderate ulcerative colitis.
For instance, On April 3, 2023, Sandoz, a prominent player in the generic and biosimilar medicine market, recently received marketing authorization from the European Commission (EC) for a citrate-free high-concentration formulation (HCF) of its biosimilar medicine Hyrimoz (adalimumab).
The approval encompasses all indications covered by the reference medicine, including rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis, and hidradenitis suppurativa.
Market Geographical Share
North America Holds a Dominant Position in the Global Inflammatory Bowel Disease Market
North America is estimated to hold around 40.7% of the total market share throughout the forecast period, owing to the rising clinical trials, the increasing acquisition and collaborations among the market players, and increasing FDA approvals are the factors expected to boost the region's growth over the forecast period.
For instance, on April 13, 2023, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine.
Furthermore, in April 2023, Merck acquired Prometheus Biosciences for $10.8 billion, which brings an inflammatory bowel disease (IBD) drug candidate and a precision medicine platform to Merck's immunology pipeline. Prometheus Biosciences has used precision medicine to identify a proprietary biomarker that may identify patients who may benefit from the IBD drug candidate, PRA023.
The drug candidate is in Phase 3 clinical trials and has the potential to become a blockbuster drug. The acquisition is intended to bolster Merck's immunology pipeline and expand its presence in the IBD market. Hence, the North American region is expected to hold the largest market share over the forecast period due to the above factors.
Market Players
The major global players in the market include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Eli Lilly Company, Merck & Co., Inc., Johnson & Johnson, Biocon Ltd., and Sanofi among others.
Russia Ukraine Conflict Analysis:
The ongoing Russia-Ukraine conflict poses potential challenges for the IBS market. Supply chain disruptions may lead to medication shortages, impacting patient access to necessary treatments. Healthcare infrastructure in affected areas, including hospitals and clinics, may suffer damage and face service disruptions, affecting the diagnosis and management of IBS.
The psychological toll of the conflict, such as stress and anxiety, can worsen IBS symptoms or trigger flare-ups in susceptible individuals. Overall, the conflict's impact on the IBS market encompasses medication availability, healthcare infrastructure, and psychological well-being. These factors suggest that the conflict has had a notable influence on the market during the forecast period.
Key Developments
- On March 16, 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
This FDA approval is the first indication for RINVOQ in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies.
- On February 27, 2023, AbbVie will present further analyses on SKYRIZI (risankizumab) in Crohn's disease (CD) and RINVOQ (upadacitinib) in ulcerative colitis (UC) as well as the investigational use of upadacitinib in CD at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), to be held March 1-4 in Copenhagen, Denmark.
AbbVie will present 24 abstracts, including four oral presentations, two digital oral presentations, and 18 posters from a broad range of studies across its inflammatory bowel disease (IBD) portfolio.
- On December 21, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC).
The FDA’s decision is expected in the second half of 2023. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod in the same patient population with the decision anticipated in the first half of 2024.
Why Purchase the Report?
- To visualize the Global Inflammatory Bowel Disease Market segmentation based on the type, route of administration, drug class, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous inflammatory bowel disease market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Inflammatory Bowel Disease Market Report Would Provide Approximately 69 Tables, 68 Figures And 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
